Remove 2022 Remove Drug Pricing Remove Pharmaceutical Companies
article thumbnail

STAT+: PhRMA dues fell almost $100 million as major drugmakers exited

STAT

WASHINGTON — Three large pharmaceutical companies left the brand-drug lobby PhRMA after the passage of Democrats’ drug pricing law in 2022. Following the exits, the organization collected $100 million less in annual membership dues, new tax filings show.

article thumbnail

STAT+: Pharma execs donated more to Democrats in campaign’s final stretch

STAT

WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. 30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drug pricing reform in decades in 2022

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers

STAT

The departure is a blow to the trade group, which represents members ranging from small biotech startups to massive pharmaceutical companies. Pfizer is a prominent member of PhRMA, the lobbying group for brand-name drug companies, and its chief executive officer, Albert Bourla, is its board treasurer.

article thumbnail

Drug Pricing and Affordability

RX Note

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Pharmaceutical industry also spent a lot of money on marketing.

article thumbnail

Five things to watch as the Biosimilars market heats up in 2022

pharmaphorum

Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 in 2022 to JPY9.498 trillion ($68.08 One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions.

article thumbnail

Divest to invest: the new normal in biopharma?

European Pharmaceutical Review

This heightened focus from regulators is shifting the type of deals pharmaceutical companies are willing to execute, Baral noted. This is compared to 64 in January to June of 2022 and 85 in the same period of 2021, despite high value Big Pharma deals in the past six months. Venture funding in 2022 came in at about $13.7